HYDERABAD: Pharma main Aurobindo Pharma on Saturday stated it has posted a 79% soar in consolidated net profit for the fourth quarter ended March 31, 2024, at Rs 907 crore as towards Rs 506 crore within the corresponding interval of monetary yr 2022-23.
This was on a 17% rise in income from operations for Q4FY24 at Rs 7580 crore as in comparison with Rs 6473 crore in Q4FY23.
For your entire FY24, the corporate registered a 64% improve in consolidated net profit at Rs 3169 crore as towards Rs 1927 crore in FY23 on a virtually 17% rise in whole income from operations at Rs 29,002 crore in FY24 from Rs 24,855 crore in FY23.
Revenues from formulations in FY24 grew practically 19% year-on-year to Rs 24,419 crore from Rs 20,579 crore in FY23 led by a 24% soar in revenues from US market (excluding Puerto Rico) to Rs 13,867 crore from Rs 11,227 crore, whereas these from Europe grew practically 12% to Rs 7166 crore in FY24 from Rs 6426 crore and that from development markets (together with India formulations gross sales) rose 29% to Rs 2517 crore from Rs 1951 crore.
The solely exception was ARV (anti-retroviral) gross sales that fell 11% to Rs 868 crore in FY24 from Rs 976 crore in FY23. On the opposite hand, whole API (energetic pharmaceutical substances) gross sales jumped 21% to Rs 4241 crore from Rs 3848 crore in FY23.
Commenting on the efficiency, Aurobindo Pharma vice-chairman and managing director Ok Nithyananda Reddy stated the efficiency for the quarter and yr was sturdy, supported by enlargement into new markets, product launches and steady pricing. “Our improved capacity utilisation has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year while stabilising the operations of the recently commercialised facilities,” he stated.
Meanwhile the corporate knowledgeable the bourses that the US Food and Drug Administration (USFDA) has labeled the inspection standing of Unit III of its wholly owned subsidiary Eugia Pharma Specialties Ltd as official motion indicated (OAI).
The US drug watchdog had inspected the formulations facility at Pashamylaram in Patancheru mandal of Sangareddy district of Telangana from January 22 to February 2, 2024.
“The company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis,” the corporate stated in a regulatory submitting.
This was on a 17% rise in income from operations for Q4FY24 at Rs 7580 crore as in comparison with Rs 6473 crore in Q4FY23.
For your entire FY24, the corporate registered a 64% improve in consolidated net profit at Rs 3169 crore as towards Rs 1927 crore in FY23 on a virtually 17% rise in whole income from operations at Rs 29,002 crore in FY24 from Rs 24,855 crore in FY23.
Revenues from formulations in FY24 grew practically 19% year-on-year to Rs 24,419 crore from Rs 20,579 crore in FY23 led by a 24% soar in revenues from US market (excluding Puerto Rico) to Rs 13,867 crore from Rs 11,227 crore, whereas these from Europe grew practically 12% to Rs 7166 crore in FY24 from Rs 6426 crore and that from development markets (together with India formulations gross sales) rose 29% to Rs 2517 crore from Rs 1951 crore.
The solely exception was ARV (anti-retroviral) gross sales that fell 11% to Rs 868 crore in FY24 from Rs 976 crore in FY23. On the opposite hand, whole API (energetic pharmaceutical substances) gross sales jumped 21% to Rs 4241 crore from Rs 3848 crore in FY23.
Commenting on the efficiency, Aurobindo Pharma vice-chairman and managing director Ok Nithyananda Reddy stated the efficiency for the quarter and yr was sturdy, supported by enlargement into new markets, product launches and steady pricing. “Our improved capacity utilisation has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year while stabilising the operations of the recently commercialised facilities,” he stated.
Meanwhile the corporate knowledgeable the bourses that the US Food and Drug Administration (USFDA) has labeled the inspection standing of Unit III of its wholly owned subsidiary Eugia Pharma Specialties Ltd as official motion indicated (OAI).
The US drug watchdog had inspected the formulations facility at Pashamylaram in Patancheru mandal of Sangareddy district of Telangana from January 22 to February 2, 2024.
“The company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis,” the corporate stated in a regulatory submitting.
